

Jason D Wright

List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/665371/publications.pdf](https://exaly.com/author-pdf/665371/publications.pdf)

Version: 2025-02-01

566

PR articles

16,838

PR citations

14772

62

PR h-index

14640

125

g-index

621

documents

20094

doc citations

11668

71

h-index

25902

citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence and Predictors of Follow-up Endoscopic Biopsy in Patients With Celiac Disease in the United States. <i>Journal of Clinical Gastroenterology</i> , 2025, 59, 155-160.	2.2	0
2	Approach to radical hysterectomy for cervical cancer after the Laparoscopic Approach to Cervical Cancer trial and associated complications: a National Surgical Quality Improvement Program study. <i>American Journal of Obstetrics and Gynecology</i> , 2025, 232, 208.e1-208.e11.	2.4	14
3	Assessment of early death in gynecologic malignancy in the United States. <i>International Journal of Gynecology and Obstetrics</i> , 2025, 168, 838-840.	1.8	1
4	Transverse versus Vertical Incision in the Surgical Management of Placenta Accreta Spectrum. <i>American Journal of Perinatology</i> , 2025, 42, 1200-1205.	1.7	0
5	Patient and Surgeon Attitudes Toward Opportunistic Salpingectomy During Nongynecological Surgeries for the Prevention of Ovarian Cancer: A Qualitative Study. <i>Journal of Surgical Oncology</i> , 2025, 131, 1149-1156.	1.5	1
6	Trends and comparisons of palliative care utilization for patients with metastatic gynecologic malignancy. <i>International Journal of Gynecological Cancer</i> , 2025, 35, 101631.	2.7	2
7	Estimating high-grade serous fallopian tubal carcinoma in the era of tubal hypothesis. <i>International Journal of Gynecological Cancer</i> , 2025, 35, 101657.	2.7	2
8	Histology-specific prognostic significance of isolated tumor cells, micrometastases, and macrometastases in endometrial cancer. <i>Gynecologic Oncology</i> , 2025, 194, 51-59.	3.0	2
9	Temporal Trends And Outcomes Of Sentinel Lymph Node Biopsy For Cervical Cancer In The United States. <i>International Journal of Gynecological Cancer</i> , 2025, 35, 100580.	2.7	0
10	Ultrasound-based versus immediate biopsy-based management of postmenopausal bleeding in non-Hispanic Black and non-Hispanic White individuals. <i>Gynecologic Oncology</i> , 2025, 194, 105-111.	3.0	2
11	How to talk with surgical patients about risk: The example of a novel surgical strategy. <i>Heliyon</i> , 2025, 11, e42969.	3.3	0
12	Examining the Association of Body Mass Index and Complications When Including Sentinel Lymph Node Biopsy in Minimally Invasive Surgery for Endometrial Intraepithelial Neoplasia. <i>Cancers</i> , 2025, 17, 1257.	3.8	0
13	Peer influence on physicians in adopting opportunistic salpingectomy at the time of hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2025, 233, 446.e1-446.e13.	2.4	0
14	Temporal trends of sentinel lymph node biopsy without lymphadenectomy at cervical cancer surgery. <i>Gynecologic Oncology</i> , 2025, 196, 182-191.	3.0	4
15	Nationwide assessment of COVID-19 ventilator and non-invasive respiratory support burden during the early pandemic in the United States. <i>Scientific Reports</i> , 2025, 15, .	3.4	0
16	Cytology-negative, non-myoinvasive stage IC serous endometrial cancer: Assessment of adjuvant chemotherapy omission. <i>Gynecologic Oncology</i> , 2025, 198, 146-153.	3.0	1
17	Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2025, 34, 1156-1166.	1.1	2
18	Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2). <i>Gynecologic Oncology</i> , 2025, 199, 152-158.	3.0	1

#	ARTICLE	IF	CITATIONS
19	Use and Outcomes of Medication for Opioid Use Disorder Among Patients With Opioid Use Disorder Undergoing Surgery. <i>Annals of Surgery Open</i> , 2025, 6, e598.	1.4	1
20	Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability. <i>Gynecologic Oncology</i> , 2025, 201, 69-75.	3.0	2
21	Risk for and temporal trends in cesarean surgical complications. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2024, 35, 6489-6497.	1.7	3
22	Longitudinal Risk Adjustment for Maternal End-Organ Injury and Death. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2024, 35, 6346-6352.	1.7	1
23	Maternal morbidity and mortality associated with epilepsy. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2024, 35, 7917-7923.	1.7	12
24	Pregnancy costs with commercial insurance. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2024, 35, 10143-10151.	1.7	2
25	Trends in tubal sterilisation in young women in the United States. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2024, 131, 112-114.	3.1	1
26	Ambient particulate matter air pollution exposure and ovarian cancer incidence in the USA: An ecological study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2024, 131, 690-698.	3.1	12
27	Racial and Ethnic Disparities in the Use of Robot-Assisted Surgery and Minimally Invasive Surgery in Pelvic Cancer Treatment: A Systematic Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2024, 33, 20-32.	1.1	5
28	Black-White differences in uterine cancer symptomatology and stage at diagnosis. <i>Gynecologic Oncology</i> , 2024, 180, 118-125.	3.0	10
29	Regional Variation in Antenatal Late Preterm Steroid Use Following the ALPS Trial. <i>JAMA Network Open</i> , 2024, 7, e2350830.	6.6	5
30	Does the Adoption of Molecular Testing Cause Decreased Thyroidectomy Rates in a National Cohort? A Quasiexperimental Study of High- Versus Low-Adoption States. <i>Thyroid</i> , 2024, 34, 388-398.	4.4	14
31	Low-grade endometrioid endometrial cancer with adnexal only metastasis: Evaluation of de-escalation of adjuvant therapy. <i>European Journal of Cancer</i> , 2024, 200, 113533.	4.9	8
32	Excess morbidity and mortality associated with underuse of estrogen replacement therapy in premenopausal women who undergo surgical menopause. <i>American Journal of Obstetrics and Gynecology</i> , 2024, 230, 653.e1-653.e17.	2.4	3
33	Nationwide assessment of practice variability in the utilization of hysteropexy at laparoscopic apical suspension for uterine prolapse. <i>AJOG Global Reports</i> , 2024, 4, 100322.	1.3	2
34	Racial and ethnic differences in early death among gynecologic malignancy. <i>American Journal of Obstetrics and Gynecology</i> , 2024, 231, 231.e1-231.e11.	2.4	6
35	Lymph Node Isolated Tumor Cells in Patients With Endometrial Cancer. <i>JAMA Network Open</i> , 2024, 7, e240988.	6.6	11
36	Increasing utilization of intrauterine device insertion at hysteroscopic endometrial evaluation for patients with endometrial hyperplasia. <i>Archives of Gynecology and Obstetrics</i> , 2024, 309, 2709-2718.	1.9	1

#	ARTICLE	IF	CITATIONS
37	Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning. <i>Gynecologic Oncology</i> , 2024, 186, 9-16.	3.0	7
38	Cesarean hysterectomy for placenta accreta spectrum: Surgeon specialty-specific assessment. <i>Gynecologic Oncology</i> , 2024, 186, 85-93.	3.0	5
39	Cost-effectiveness of BRCA1 testing at time of obstetrical prenatal carrier screening for cancer prevention. <i>American Journal of Obstetrics and Gynecology</i> , 2024, 231, 330.e1-330.e14.	2.4	9
40	Prognostic performance of the 2023 FIGO staging schema for endometrial cancer. <i>Gynecologic Oncology</i> , 2024, 187, 37-45.	3.0	21
41	Trends in uterine cancer incidence in the United States: The contribution of age, period and cohort effects. <i>Gynecologic Oncology</i> , 2024, 187, 151-162.	3.0	9
42	Incidence of induced abortion among commercially insured pregnant patients with cancer. <i>Contraception</i> , 2024, 138, 110511.	1.2	1
43	Patterns of use of primary and first-line chemotherapy for recurrence among patients with cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2024, 34, 1001-1010.	2.7	1
44	Sociodemographic factors associated with antenatal steroid use among late preterm births. <i>American Journal of Obstetrics & Gynecology</i> MFM, 2024, 6, 101397.	2.1	2
45	Primary Cytoreduction and Survival for Patients With Less-Common Epithelial Ovarian Cancer. <i>JAMA Network Open</i> , 2024, 7, e2417775.	6.6	4
46	Temporal trends of adolescents and young adults (AYA) with gynecologic malignancy in the United States. <i>Gynecologic Oncology Reports</i> , 2024, 54, 101455.	0.7	0
47	Fragmented Surgical Cancer Care—A Growing Divide. <i>JCO Oncology Practice</i> , 2024, 20, 1788-1789.	3.0	0
48	Fertility-preserving treatment for stage IA endometrial cancer: a systematic review and meta-analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2024, 231, 599-610.e17.	2.4	15
49	Incorporation of immunotherapy and biological targeted therapy in primary anti-cancer treatment in gynecologic malignancy. <i>International Journal of Gynecology and Obstetrics</i> , 2024, 167, 1257-1259.	1.8	0
50	Secondary databases in gynecologic cancer research. <i>International Journal of Gynecological Cancer</i> , 2024, 34, 1619-1629.	2.7	22
51	Racial and ethnic disparities in robot-assisted radical prostatectomy: testing the physician-level segregated and differential treatment hypotheses. <i>JNCI Cancer Spectrum</i> , 2024, 8, .	2.9	2
52	Stage IC grade 1 endometrioid adenocarcinoma of the ovary: assessment of post-operative chemotherapy de-escalation. <i>International Journal of Gynecological Cancer</i> , 2024, 34, 1603-1611.	2.7	2
53	Antihypertensive medication prescription dispensation among pregnant women in the United States: A cohort study. <i>American Heart Journal</i> , 2024, 278, 5-13.	2.9	1
54	Weight-loss therapy in patients with obesity with endometrial intraepithelial neoplasia and uterine cancer. <i>Gynecologic Oncology</i> , 2024, 190, 78-83.	3.0	2

#	ARTICLE	IF	CITATIONS
55	Tubal Sterilization Rates by State Abortion Laws After the Dobbs Decision. JAMA - Journal of the American Medical Association, 2024, 332, 1204.	16.6	17
56	Diagnostic experiences of Black and White patients with uterine cancer: A qualitative study. Gynecologic Oncology, 2024, 191, 67-73.	3.0	2
57	Risk factors for major complications following pelvic exenteration: A NSQIP study. European Journal of Surgical Oncology, 2024, 50, 108761.	0.9	4
58	Adjuvant therapy de-escalation for stage I uterine leiomyosarcoma: A systematic review and meta-analysis. Gynecologic Oncology, 2024, 191, 219-227.	3.0	4
59	Suicide Deaths Among Adolescent and Young Adult Patients With Cancer. JAMA Network Open, 2024, 7, e2442964.	6.6	3
60	Postthrombotic Syndrome and Chronic Pulmonary Embolism after Obstetric Venous Thromboembolism. American Journal of Perinatology, 2023, 40, 022-024.	1.7	1
61	Prevalence of anxiety and depressive disorders in pregnant women with malignancy. International Journal of Gynecology and Obstetrics, 2023, 160, 635-640.	1.8	4
62	Association between neighborhood socioeconomic status, built environment and SARS-CoV-2 infection among cancer patients treated at a Tertiary Cancer Center in New York City. Cancer Reports, 2023, 6, .	1.7	3
63	Impact of a Hospital-Based Specialty Pharmacy in Partnership With a Care Coordination Organization on Time to Delivery and Receipt of Oral Anticancer Drugs. JCO Oncology Practice, 2023, 19, e326-e335.	3.0	5
64	Prescription of hormone replacement therapy among cervical cancer patients with treatment-induced premature menopause. International Journal of Gynecological Cancer, 2023, 33, 26-34.	2.7	10
65	Risk for adverse maternal outcomes among women with chronic hypertension. BJOG: an International Journal of Obstetrics and Gynaecology, 2023, 130, 621-635.	3.1	0
66	Medical and surgical retreatment for uterine leiomyoma after myomectomy. BJOG: an International Journal of Obstetrics and Gynaecology, 2023, 130, 835-837.	3.1	0
67	Intraoperative rupture and chemotherapy use in stage I ovarian cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2023, 284, 200-202.	0.9	2
68	Racial disparities in diagnostic evaluation of uterine cancer among Medicaid beneficiaries. Journal of the National Cancer Institute, 2023, 115, 636-643.	4.6	18
69	The potential role of GLP-1 receptor agonist targeting in fertility-sparing treatment in obese patients with endometrial malignant pathology: a call for research. Expert Review of Anticancer Therapy, 2023, 23, 385-395.	2.5	8
70	A Transcriptome-Based Precision Oncology Platform for Patient Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies. Cancer Discovery, 2023, 13, 1386-1407.	25.1	32
71	Direct oral anticoagulant (DOACs) prescribing practices of members of the Society of Gynecologic Oncology and American Society of Clinical Oncology. Gynecologic Oncology, 2023, 173, 68-73.	3.0	2
72	Lymph node evaluation for endometrial hyperplasia: a nationwide analysis of minimally invasive hysterectomy in the ambulatory setting. Surgical Endoscopy and Other Interventional Techniques, 2023, 37, 6163-6171.	2.3	7

#	ARTICLE	IF	CITATIONS
73	Cancer-directed surgery in patients with metastatic cancer: A systematic review and meta-analysis of randomized evidence. <i>Cancer Medicine</i> , 2023, 12, 14072-14083.	2.6	5
74	Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas. <i>JAMA Network Open</i> , 2023, 6, e2318602.	6.6	19
75	Increasing trends of cervical conization with lymph node evaluation for fertility-sparing surgery in early cervical cancer. <i>Gynecologic Oncology</i> , 2023, 173, 122-129.	3.0	6
76	Trends in the use of indocyanine green for sentinel lymph node mapping in vulvar cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2023, 229, 466-468.	2.4	4
77	Temporal trends of failure-to-rescue following perioperative complications in vulvar cancer surgery in the United States. <i>Gynecologic Oncology</i> , 2023, 177, 1-8.	3.0	3
78	Placenta previa percreta with surrounding organ involvement: a proposal for management. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 1633-1644.	2.7	11
79	National Estimates of Gender-Affirming Surgery in the US. <i>JAMA Network Open</i> , 2023, 6, e2330348.	6.6	141
80	Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis. <i>JNCI Cancer Spectrum</i> , 2023, 7, .	2.9	22
81	Trends, Characteristics, and Maternal Morbidity Associated With Unhoused Status in Pregnancy. <i>JAMA Network Open</i> , 2023, 6, e2326352.	6.6	32
82	Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 908-918.	22.9	41
83	Risk factors for developing both primary breast and primary ovarian cancer: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 190, 104081.	5.0	12
84	Timeliness of diagnostic evaluation for postmenopausal bleeding: A retrospective cohort study using claims data. <i>PLoS ONE</i> , 2023, 18, e0289692.	2.3	4
85	Disparities with influenza vaccine use in long-term survivors of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 203, 111-119.	2.4	0
86	Validation of the 2023 FIGO staging schema for advanced endometrial cancer. <i>European Journal of Cancer</i> , 2023, 193, 113316.	4.9	26
87	TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes. <i>Gynecologic Oncology</i> , 2023, 178, 44-53.	3.0	30
88	Robot-Assisted Surgery and Racial and Ethnic Disparities in Post-Prostatectomy Outcomes Among Prostate Cancer Patients. <i>Annals of Surgical Oncology</i> , 2023, 31, 1373-1383.	2.3	3
89	Trends in Cancer-Directed Surgery Rates Associated with the COVID-19 Pandemic. <i>Annals of Surgical Oncology</i> , 2023, , .	2.3	0
90	Decision to Incision and Risk for Fetal Acidemia, Low Apgar Scores, and Hypoxic Ischemic Encephalopathy. <i>American Journal of Perinatology</i> , 2022, 39, 416-424.	1.7	5

#	ARTICLE	IF	CITATIONS
91	Vancomycin during delivery hospitalizations for women with group B streptococcus. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 898-906.	1.7	1
92	Endometrial Sampling for Preoperative Diagnosis of Uterine Leiomyosarcoma. <i>Journal of Minimally Invasive Gynecology</i> , 2022, 29, 119-127.	0.8	10
93	Trends in and complications associated with mental health condition diagnoses during delivery hospitalizations. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 405.e1-405.e16.	2.4	31
94	Postpartum cardiac readmissions among women without a cardiac diagnosis at delivery. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 4768-4774.	1.7	5
95	Minimally invasive surgery for suspected early-stage ovarian cancer; a cost-effectiveness study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 777-784.	3.1	11
96	Comparison of Perioperative Outcomes in Heart Failure Patients With Reduced Versus Preserved Ejection Fraction After Noncardiac Surgery. <i>Annals of Surgery</i> , 2022, 275, 807-815.	4.6	13
97	Sentinel lymph node biopsy for stage II endometrial cancer: Recent utilization and outcome in the United States. <i>Gynecologic Oncology</i> , 2022, 164, 46-52.	3.0	17
98	Hospital surgical volume-outcome relationship in caesarean hysterectomy for placenta accreta spectrum. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 986-993.	3.1	16
99	Long-term outcomes of vaginal hysterectomy for endometrial cancer. <i>Gynecologic Oncology</i> , 2022, 164, 105-112.	3.0	3
100	Association Between Neighborhood Socioeconomic Inequality and Cervical Cancer Incidence Rates in New York City. <i>JAMA Oncology</i> , 2022, 8, 159.	14.4	14
101	Perioperative and persistent opioid utilization following pancreatectomy in the United States. <i>Hpb</i> , 2022, 24, 912-924.	0.3	3
102	Adverse Outcomes during Postpartum Readmissions after Deliveries Complicated by Hypertensive Disorders of Pregnancy. <i>American Journal of Perinatology</i> , 2022, 39, 699-706.	1.7	15
103	Out-of-network bills among privately insured patients undergoing hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 543.e1-543.e45.	2.4	4
104	Patterns of use and outcomes of adjuvant bevacizumab therapy prior to regulatory approval in women with newly diagnosed ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2022, 305, 1647-1654.	1.9	2
105	Population-level trends and outcomes of sentinel lymph node biopsy in vulvar cancer surgery in the United States. <i>Gynecologic Oncology</i> , 2022, 164, 651-657.	3.0	7
106	Validation of the 2021 FIGO staging schema for advanced vulvar cancer. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 474-479.	2.7	6
107	Authors' reply re: Covariate analysis query: Hospital surgical volume-outcome relationship in caesarean hysterectomy for placenta accreta spectrum. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1411-1412.	3.1	0
108	Uptake and outcomes of sentinel lymph node mapping in women undergoing minimally invasive surgery for endometrial cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1591-1599.	3.1	8

#	ARTICLE	IF	CITATIONS
109	COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemic. <i>Gynecologic Oncology</i> , 2022, 164, 304-310.	3.0	15
110	Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer. <i>Gynecologic Oncology</i> , 2022, 164, 341-347.	3.0	3
111	Surgical Complications and Hospital Costs in Robot-Assisted Versus Conventional Laparoscopic Hysterectomy With Concurrent Sacrocolpopexy: Analysis of the Nationwide Readmissions Database. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2022, 28, e142-e148.	1.3	10
112	Nationwide Estimates of Annual Inpatient and Outpatient Hysterectomies Performed in the United States. <i>Obstetrics and Gynecology</i> , 2022, 139, 446-448.	1.9	50
113	Characterizing isolated tumor cells in regional lymph nodes of early endometrial cancer. <i>Gynecologic Oncology</i> , 2022, 165, 264-269.	3.0	10
114	Hormonal therapy or chemotherapy for early-stage, low-grade endometrial cancer with malignant peritoneal cytology: A comparative effectiveness study. <i>Gynecologic Oncology</i> , 2022, 165, 353-360.	3.0	4
115	Outcomes during delivery hospitalisations with inflammatory bowel disease. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1073-1083.	3.1	8
116	Incorporation of sentinel lymph node biopsy in cervical cancer surgery: Recent U.S. trends. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1407-1413.	0.9	13
117	Safety Warning about Laparoscopic Power Morcellation in Hysterectomy: A Cost-Effectiveness Analysis of National Impact. <i>Women S Health Reports</i> , 2022, 3, 369-384.	1.0	2
118	Population incidence and characteristics of secondary breast cancer after uterine cancer: a competing risk analysis. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 865-874.	1.9	1
119	Pathologic characteristics, patterns of care, and outcomes of Asian-Americans and Pacific islanders with uterine cancer. <i>Gynecologic Oncology</i> , 2022, 165, 160-168.	3.0	7
120	Trends in human papillomavirus vaccination among women aged 27 to 45 years, from 2017 to 2019. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 568-570.e1.	2.4	0
121	Association between hospital treatment volume and major complications in ovarian hyperstimulation syndrome. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2022, 272, 240-246.	0.9	0
122	Patterns of cervical cancer screening among Medicaid beneficiaries. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 1104-1111.	3.1	3
123	Cancer-Specific Mortality in Asian American Women Diagnosed with Gynecologic Cancer: A Nationwide Population-Based Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 578-587.	1.1	7
124	Racial and ethnic differences in the adoption of opportunistic salpingectomy for ovarian cancer prevention in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 257.e1-257.e22.	2.4	15
125	Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2022, 166, 181-187.	3.0	8
126	Adjuvant and first line chemotherapy use for endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2022, 41, 101002.	0.7	12

#	ARTICLE	IF	CITATIONS
127	Utilization and Outcomes of Sentinel Lymph Node Biopsy for Early Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2022, 139, 809-820.	1.9	23
128	Prophylactic endovascular internal iliac balloon placement during cesarean hysterectomy for placenta accreta spectrum. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2022, 4, 100657.	2.1	6
129	New persistent opioid use among adolescents and young adults with sarcoma. <i>Cancer</i> , 2022, 128, 2777-2785.	4.0	13
130	Sentinel lymph node mapping for endometrial cancer: Opportunity for medical waste reform. <i>Gynecologic Oncology</i> , 2022, 166, 162-164.	3.0	7
131	Utilization of sentinel lymph node biopsy in the early ovarian cancer surgery. <i>Archives of Gynecology and Obstetrics</i> , 2022, 307, 525-532.	1.9	8
132	Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1032-1038.	2.7	12
133	Assessment of Severe Maternal Morbidity and Mortality in Pregnancies Complicated by Cancer in the US. <i>JAMA Oncology</i> , 2022, 8, 1213.	14.4	26
134	Association between immigrant status and advanced cancer patients' location and quality of death. <i>Cancer</i> , 2022, 128, 3352-3359.	4.0	9
135	Efficacy of a password-protected, pill-dispensing device with mail return capacity to enhance disposal of unused opioids after cancer surgery. <i>Cancer</i> , 2022, 128, 3392-3399.	4.0	3
136	Relative importance of individual insurance status and hospital payer mix on survival for women with cervical cancer. <i>Gynecologic Oncology</i> , 2022, 166, 552-560.	3.0	7
137	Increasing rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease: a nationwide analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 1157-1167.	3.7	32
138	Malignant peritoneal cytology in endometrial cancer: a contemporary review. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 947-955.	2.5	9
139	Utilization of lymph node evaluation at hysterectomy for cervical carcinoma in situ. <i>Journal of Surgical Oncology</i> , 2022, 126, 1543-1550.	1.5	3
140	Gynecologic oncologists in surgery for placenta accreta spectrum: a survey for practice, experience, and interest. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1433-1442.	2.7	11
141	Factors Associated With Patients Not Receiving Oral Anticancer Drugs. <i>JAMA Network Open</i> , 2022, 5, e2236380.	6.6	8
142	Obstetric outcomes among women with a liver transplant. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, 34, 2932-2937.	1.7	9
143	Patterns of care for women with placenta accreta spectrum. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, 34, 3370-3376.	1.7	10
144	Hospital Safety-Net Burden and Risk for Readmissions and Severe Maternal Morbidity. <i>American Journal of Perinatology</i> , 2021, 38, e359-e366.	1.7	5

#	ARTICLE	IF	CITATIONS
145	Receipt of Proton-Pump Inhibitors during Pregnancy and Risk for Preeclampsia. <i>American Journal of Perinatology</i> , 2021, 38, 1519-1525.	1.7	12
146	Postpartum hemorrhage and risk for postpartum readmission. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, 34, 187-194.	1.7	34
147	Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events. <i>Gynecologic Oncology</i> , 2021, 160, 438-444.	3.0	17
148	The Role of Minimally Invasive Surgery in the Care of Women with Ovarian Cancer: A Systematic Review and Meta-analysis. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 537-543.	0.8	24
149	Less radical surgery for early-stage cervical cancer: a systematic review. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 348-358.e5.	2.4	34
150	Proposal of an endometrial cancer staging schema with stage-specific incorporation of malignant peritoneal cytology. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 319-321.	2.4	14
151	Racial disparities in patients with coronavirus disease 2019 infection and gynecologic malignancy. <i>Cancer</i> , 2021, 127, 1057-1067.	4.0	8
152	Cost of care for the initial management of cervical cancer in women with commercial insurance. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 286.e1-286.e11.	2.4	18
153	National trends and outcomes of morbidly obese women who underwent inpatient hysterectomy for benign gynecological disease in the USA. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 459-470.	2.6	13
154	Postpartum Psychiatric Admissions in the United States. <i>American Journal of Perinatology</i> , 2021, 38, 115-121.	1.7	8
155	Surveillance in Older Women With Incidental Ovarian Cysts: Maximal Projected Benefits by Age and Comorbidity Level. <i>Journal of the American College of Radiology</i> , 2021, 18, 10-18.	2.3	3
156	Quantitative analysis of abnormalities in gynecologic cytopathology with deep learning. <i>Laboratory Investigation</i> , 2021, 101, 513-524.	3.2	16
157	Inappropriateness of Proton Pump Inhibitors After Hospital Discharge Is Associated with Thirty-Day Hospital Readmission. <i>Digestive Diseases and Sciences</i> , 2021, 67, 817-825.	2.1	6
158	Association Between Adjuvant Therapy and Survival in Stage II-III Endometrial Cancer: Influence of Malignant Peritoneal Cytology. <i>Annals of Surgical Oncology</i> , 2021, 28, 7591-7603.	2.3	12
159	Trends in Use of Myomectomy for the Surgical Management of Uterine Leiomyomas in Perimenopausal and Postmenopausal Women. <i>Obstetrics and Gynecology</i> , 2021, 137, 843-845.	1.9	3
160	Utilization and perioperative outcome of minimally invasive pelvic exenteration in gynecologic malignancies: A national study in the United States. <i>Gynecologic Oncology</i> , 2021, 161, 39-45.	3.0	27
161	Overuse of Cervical Cancer Screening Tests Among Women With Average Risk in the United States From 2013 to 2014. <i>JAMA Network Open</i> , 2021, 4, e218373.	6.6	30
162	Uptake and Outcomes of Sentinel Lymph Node Mapping in Women With Atypical Endometrial Hyperplasia. <i>Obstetrics and Gynecology</i> , 2021, 137, 924-934.	1.9	28

#	ARTICLE	IF	CITATIONS
163	Racial and Ethnic Disparities in Peripartum Hysterectomy Risk and Outcomes. <i>American Journal of Perinatology</i> , 2021, 38, 999-1009.	1.7	10
164	The effect of frailty on postoperative readmissions, morbidity, and mortality in endometrial cancer surgery. <i>Gynecologic Oncology</i> , 2021, 161, 353-360.	3.0	22
165	Association between definitive chemoradiotherapy wait-time and survival in locally-advanced cervical cancer: Implications during the coronavirus pandemic. <i>Gynecologic Oncology</i> , 2021, 161, 414-421.	3.0	8
166	Risk of Postpartum Flare Hospitalizations in Patients with Inflammatory Bowel Disease Persists After Six Months. <i>Digestive Diseases and Sciences</i> , 2021, 67, 4278-4286.	2.1	2
167	Use of fertility preservation services in male reproductive-aged cancer patients. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100716.	0.7	13
168	Hospital variation in responses to safety warnings about power morcellation in hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 589.e1-589.e13.	2.4	4
169	Services and payer mix of Black-serving hospitals and related severe maternal morbidity. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 605.e1-605.e13.	2.4	5
170	Trends in ovarian conservation and association with survival in premenopausal patients with stage I leiomyosarcoma. <i>Gynecologic Oncology</i> , 2021, 161, 734-740.	3.0	3
171	Paradigm shift from tubal ligation to opportunistic salpingectomy at cesarean delivery in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 399.e1-399.e32.	2.4	36
172	Trends in peritoneal cytology evaluation at hysterectomy for endometrial cancer in the United States. <i>Gynecologic Oncology</i> , 2021, 161, 710-719.	3.0	15
173	Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival. <i>Gynecologic Oncology</i> , 2021, 162, 56-64.	3.0	17
174	Disparities in Access to High-Volume Surgeons Within High-Volume Hospitals for Hysterectomy. <i>Obstetrics and Gynecology</i> , 2021, 138, 208-217.	1.9	24
175	Decreasing utilization of minimally invasive hysterectomy for cervical cancer in the United States. <i>Gynecologic Oncology</i> , 2021, 162, 43-49.	3.0	30
176	Association between hysterectomy wait-time and all-cause mortality for micro-invasive cervical cancer: treatment implications during the coronavirus pandemic. <i>Archives of Gynecology and Obstetrics</i> , 2021, 306, 283-287.	1.9	3
177	Intraoperative Rupture of the Ovarian Capsule in Early-Stage Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2021, 138, 261-271.	1.9	8
178	Precision medicine testing in ovarian cancer: The growing inequity between patients with commercial vs medicaid insurance. <i>Gynecologic Oncology</i> , 2021, 162, 18-23.	3.0	16
179	Care Delivery Impact of the COVID-19 Pandemic on Breast Cancer Care. <i>JCO Oncology Practice</i> , 2021, 17, e1215-e1224.	3.0	50
180	Physician attitudes and knowledge on prophylactic salpingectomy in perimenopausal patients. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100824.	0.7	8

#	ARTICLE	IF	CITATIONS
181	Cost-effectiveness Analysis of Genotype-Specific Surveillance and Preventive Strategies for Gynecologic Cancers Among Women With Lynch Syndrome. <i>JAMA Network Open</i> , 2021, 4, e2123616.	6.6	14
182	Adherence to PARP inhibitor therapy among women with ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 262-268.	3.0	10
183	Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer. <i>JAMA Oncology</i> , 2021, 7, 1782.	14.4	38
184	Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 237.e1-237.e24.	2.4	45
185	Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer. <i>Gynecologic Oncology</i> , 2021, 162, 599-605.	3.0	8
186	Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy. <i>European Journal of Cancer</i> , 2021, 157, 59-62.	4.9	5
187	Trends in the Use of Minimally Invasive Adnexal Surgery in the United States. <i>Obstetrics and Gynecology</i> , 2021, 138, 738-746.	1.9	11
188	Neoadjuvant chemotherapy for advanced stage endometrial cancer: A systematic review. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100887.	0.7	24
189	Preeclampsia outcomes at delivery and race. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2020, 33, 3619-3626.	1.7	77
190	Oral Opioid Use during Vaginal Delivery Hospitalizations. <i>American Journal of Perinatology</i> , 2020, 37, 390-397.	1.7	1
191	Postpartum length of stay and risk for readmission among women with preeclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2020, 33, 1086-1094.	1.7	42
192	Effect of regionalization of endometrial cancer care on site of care and patient travel. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 58.e1-58.e10.	2.4	12
193	Fragmentation of postoperative care after surgical management of ovarian cancer at 30 days and 90 days. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 255.e1-255.e20.	2.4	21
194	Opioid Use Disorder during Antepartum and Postpartum Hospitalizations. <i>American Journal of Perinatology</i> , 2020, 37, 1467-1475.	1.7	9
195	Maternal Age and Preeclampsia Outcomes during Delivery Hospitalizations. <i>American Journal of Perinatology</i> , 2020, 37, 044-052.	1.7	35
196	Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1133-1141.e3.	6.0	62
197	Populational trends and outcomes of postoperative radiotherapy for high-risk early-stage cervical cancer with lymph node metastasis: concurrent chemo-radiotherapy versus radiotherapy alone. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 484.e1-484.e15.	2.4	19
198	Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. <i>Cancer</i> , 2020, 126, 1541-1549.	4.0	19

#	ARTICLE	IF	CITATIONS
199	Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models. <i>Gynecologic Oncology</i> , 2020, 156, 701-709.	3.0	4
200	Hospital surgical volume and perioperative mortality of pelvic exenteration for gynecologic malignancies. <i>Journal of Surgical Oncology</i> , 2020, 121, 402-409.	1.5	22
201	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 949-950.	2.4	0
202	Effect of frailty on postoperative readmissions and cost of care for ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 426-433.	3.0	33
203	Intradepartmental redeployment of faculty and staff. <i>Seminars in Perinatology</i> , 2020, 44, 151299.	2.3	2
204	Toxicity after adjuvant therapy for stage III uterine cancer. <i>Gynecologic Oncology</i> , 2020, 159, 737-743.	3.0	4
205	Using machine learning to create prognostic systems for endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 159, 744-750.	3.0	40
206	Minimally invasive radical hysterectomy for early-stage cervical cancer: Volume-outcome relationship in the early experience period. <i>Gynecologic Oncology</i> , 2020, 158, 390-396.	3.0	16
207	Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infection. <i>Gynecologic Oncology</i> , 2020, 159, 618-622.	3.0	10
208	Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 159, 43-51.	3.0	40
209	COVID-19 outcomes of patients with gynecologic cancer in New York City. <i>Cancer</i> , 2020, 126, 4294-4303.	4.0	56
210	Associations Between Built Environment, Neighborhood Socioeconomic Status, and SARS-CoV-2 Infection Among Pregnant Women in New York City. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 390.	16.6	156
211	Trends in venous thromboembolism prophylaxis in gynecologic surgery for benign and malignant indications. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 935-945.	1.9	4
212	Insurance-Associated Disparities in Opioid Use and Misuse Among Patients Undergoing Gynecologic Surgery for Benign Indications. <i>Obstetrics and Gynecology</i> , 2020, 136, 565-575.	1.9	11
213	The Volume-Outcome Paradigm for Gynecologic Surgery: Clinical and Policy Implications. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 252-265.	1.2	21
214	Effect of delay in surgical therapy for early-stage cervical cancer: An implication in the coronavirus pandemic. <i>European Journal of Cancer</i> , 2020, 139, 173-176.	4.9	10
215	Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016. <i>JAMA Network Open</i> , 2020, 3, e2017517.	6.6	43
216	Triple stimulation (TriStim) before bilateral oophorectomy in a young woman with ovarian cancer: a case report and review of the literature. <i>Fertility Research and Practice</i> , 2020, 6, .	3.8	5

#	ARTICLE	IF	CITATIONS
217	The effect of guideline-concordant care in mitigating insurance status disparities in cervical cancer. <i>Gynecologic Oncology</i> , 2020, 159, 309-316.	3.0	28
218	Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes. <i>Gynecologic Oncology</i> , 2020, 158, 59-65.	3.0	16
219	Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes. <i>Gynecologic Oncology</i> , 2020, 158, 415-423.	3.0	14
220	Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer. <i>JAMA Oncology</i> , 2020, 6, 1019.	14.4	181
221	Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer. <i>JAMA Oncology</i> , 2020, 6, 1110.	14.4	56
222	Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based study. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1235-1245.	1.9	6
223	Incidence and Predictors of Diabetes Mellitus after a Diagnosis of Early-Stage Breast Cancer in the Elderly Using Real-World Data. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 201-211.	2.4	12
224	When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic. <i>Gynecologic Oncology</i> , 2020, 158, 236-243.	3.0	54
225	Maternal Race/Ethnicity, Hypertension, and Risk for Stroke During Delivery Admission. <i>Journal of the American Heart Association</i> , 2020, 9, .	4.0	72
226	Impact of hospital volume on surgical management and outcomes for early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2020, 157, 508-513.	3.0	15
227	A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 157, 329-334.	3.0	10
228	Antibiotics for 3rd and 4th Degree Vaginal Lacerations, Uterine Tamponade, and Manual Placental Extraction. <i>American Journal of Perinatology</i> , 2020, 37, 092-103.	1.7	2
229	Evolving population-based statistics for rare epithelial ovarian cancers. <i>Gynecologic Oncology</i> , 2020, 157, 3-11.	3.0	27
230	Association between hospital surgical volume and perioperative outcomes of fertility-sparing trachelectomy for cervical cancer: A national study in the United States. <i>Gynecologic Oncology</i> , 2020, 157, 173-180.	3.0	15
231	Fragmentation of postpartum readmissions in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 252.e1-252.e14.	2.4	24
232	Increasing NIH funding for academic departments of obstetrics and gynecology: a call to action. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 79.e1-79.e8.	2.4	26
233	Association of Neoadjuvant Chemotherapy With Overall Survival in Women With Metastatic Endometrial Cancer. <i>JAMA Network Open</i> , 2020, 3, e2028612.	6.6	35
234	Minimally invasive interval debulking surgery after neoadjuvant chemotherapy for metastatic ovarian cancer: a national study in the United States. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 863-866.	1.9	4

#	ARTICLE	IF	CITATIONS
235	The rapid adoption of opportunistic salpingectomy at the time of hysterectomy for benign gynecologic disease in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 721.e1-721.e18.	2.4	44
236	Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer. <i>European Journal of Cancer</i> , 2020, 133, 33-46.	4.9	47
237	Prognostic significance of lymphovascular space invasion for stage IA1 and IA2 cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 735-743.	2.7	32
238	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 538.	2.4	0
239	Sequencing of therapy in women with stage III endometrial carcinoma receiving adjuvant combination chemotherapy and radiation. <i>Gynecologic Oncology</i> , 2019, 155, 13-20.	3.0	12
240	Factors Associated with Multidisciplinary Consultations in Patients with Early Stage Breast Cancer. <i>Cancer Investigation</i> , 2019, 37, 233-241.	1.6	9
241	Use of fertility preservation services in female reproductive-aged cancer patients. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 328.e1-328.e16.	2.4	31
242	Safety of same-day discharge for minimally invasive hysterectomy for endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 239.e1-239.e11.	2.4	24
243	Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 154, 505-515.	3.0	15
244	Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data. <i>Clinical Colorectal Cancer</i> , 2019, 18, e294-e299.	2.6	6
245	Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 155, 39-50.	3.0	20
246	Neuroendocrine carcinoma of the endometrium: Disease course, treatment, and outcomes. <i>Gynecologic Oncology</i> , 2019, 155, 254-261.	3.0	22
247	Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model. <i>PLoS ONE</i> , 2019, 14, e0222828.	2.3	0
248	Decreasing Trends of Secondary Primary Colorectal Cancer among Women with Uterine Cancer: A Population-Based Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 714.	2.5	3
249	Decreasing secondary primary uterine cancer after breast cancer: A population-based analysis. <i>Gynecologic Oncology</i> , 2019, 154, 169-176.	3.0	9
250	Postpartum readmissions among women with opioid use disorder. <i>American Journal of Obstetrics & Gynecology</i> MFM, 2019, 1, 89-98.	2.1	14
251	Regionalization of care for women with ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 154, 394-400.	3.0	7
252	Age-Associated Risk of 90-Day Postoperative Mortality After Cytoreductive Surgery for Advanced Ovarian Cancer. <i>JAMA Surgery</i> , 2019, 154, 669.	8.8	8

#	ARTICLE	IF	CITATIONS
253	Trachelectomy for reproductive-aged women with early-stage cervical cancer: minimally invasive surgery versus laparotomy. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, 469.e1-469.e13.	2.4	37
254	Patterns of care and outcomes for women with uterine cancer and ovarian metastases. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 365-376.	2.7	4
255	Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 39.e1-39.e14.	2.4	39
256	Substantial Increase in Anesthesia Assistance for Outpatient Colonoscopy and Associated Cost Nationwide. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2489-2496.	6.0	35
257	Patterns of utilization and outcome of ovarian conservation for young women with minimal-risk endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 154, 45-52.	3.0	17
258	FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data. <i>Clinical Colorectal Cancer</i> , 2019, 18, 133-140.	2.6	65
259	Measuring cause-and-effect relationships without randomized clinical trials: Quasi-experimental methods for gynecologic oncology research. <i>Gynecologic Oncology</i> , 2019, 152, 533-539.	3.0	19
260	Maternal outcomes by race during postpartum readmissions. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, 484.e1-484.e10.	2.4	59
261	Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, 571.e1-571.e8.	2.4	42
262	Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study. <i>Gynecologic Oncology</i> , 2019, 153, 368-375.	3.0	57
263	Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. <i>Obstetrics and Gynecology</i> , 2019, 134, 49-57.	1.9	248
264	Impact of tumor histology on detection of pelvic and para-aortic nodal metastasis with ¹⁸ F-fluorodeoxyglucose-positron emission tomography in stage IB cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1351-1354.	2.7	8
265	Use and Misuse of Opioids After Gynecologic Surgical Procedures. <i>Obstetrics and Gynecology</i> , 2019, 134, 250-260.	1.9	59
266	Caring for Patients With Uterine Cancer in Rural and Public Hospitals in New York State. <i>Obstetrics and Gynecology</i> , 2019, 134, 1260-1268.	1.9	2
267	Chemotherapy, Radiation, or Combination Therapy for Stage III Uterine Cancer. <i>Obstetrics and Gynecology</i> , 2019, 134, 17-29.	1.9	12
268	Antibiotic Use Without Indication During Delivery Hospitalizations in the United States. <i>Obstetrics and Gynecology</i> , 2019, 134, 718-725.	1.9	11
269	Trends in Use and Effect on Survival of Simple Hysterectomy for Early-Stage Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2019, 134, 1132-1143.	1.9	32
270	Potential Consequences of Minimum-Volume Standards for Hospitals Treating Women With Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2019, 133, 1109-1119.	1.9	11

#	ARTICLE	IF	CITATIONS
271	Impact of estrogen monotherapy on survival in women with stage III-IV non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 129, 8-15.	2.6	5
272	Trends in comorbidity, acuity, and maternal risk associated with preeclampsia across obstetric volume settings. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2019, 32, 2680-2687.	1.7	14
273	Patterns of seizure prophylaxis after oncologic neurosurgery. <i>Journal of Neuro-Oncology</i> , 2019, 146, 171-180.	2.5	34
274	Estimating potential for savings for low risk endometrial cancer using the Endometrial Cancer Alternative Payment Model (ECAP): A companion paper to the Society of Gynecologic Oncology Report on the Endometrial Cancer Alternative Payment Model. <i>Gynecologic Oncology</i> , 2018, 149, 241-247.	3.0	4
275	Postpartum Thromboembolism Prophylaxis during Delivery Hospitalizations. <i>American Journal of Perinatology</i> , 2018, 35, 873-881.	1.7	14
276	Heparin-Induced Thrombocytopenia during Obstetric Hospital Admissions. <i>American Journal of Perinatology</i> , 2018, 35, 898-903.	1.7	16
277	Use of Antihypertensive Medications During Delivery Hospitalizations Complicated by Preeclampsia. <i>Obstetrics and Gynecology</i> , 2018, 131, 441-450.	1.9	44
278	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 363-364.	2.4	0
279	Racial disparities in young women with endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 148, 527-534.	3.0	57
280	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 119-120.	2.4	0
281	Trends in Sentinel Lymph Node Mapping and Adjuvant Therapy in Endometrial Carcinoma. <i>Cancer Investigation</i> , 2018, 36, 190-198.	1.6	14
282	Impact of hospital volume on racial disparities and outcomes for endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 149, 329-336.	3.0	22
283	Identifying modifiable and non-modifiable risk factors associated with prolonged length of stay after hysterectomy for uterine cancer. <i>Gynecologic Oncology</i> , 2018, 149, 545-553.	3.0	5
284	Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP). <i>Gynecologic Oncology</i> , 2018, 149, 232-240.	3.0	8
285	The role of the vaginal microbiome in gynaecological cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 309-315.	3.1	160
286	Risk for postpartum hemorrhage, transfusion, and hemorrhage-related morbidity at low, moderate, and high volume hospitals. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2018, 31, 1025-1034.	1.7	31
287	National Trends in Extended Procedures for Ovarian Cancer Debulking Surgery. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 19-25.	2.7	23
288	Rectal balloon use limits vaginal displacement, rectal dose, and rectal toxicity in patients receiving IMRT for postoperative gynecological malignancies. <i>Medical Dosimetry</i> , 2018, 43, 23-29.	0.9	3

#	ARTICLE	IF	CITATIONS
289	Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence. <i>Gynecologic Oncology</i> , 2018, 148, 19-27.	3.0	18
290	Association Between Hospital Financial Distress and Immediate Breast Reconstruction Surgery After Mastectomy Among Women With Ductal Carcinoma In Situ. <i>JAMA Surgery</i> , 2018, 153, 344.	8.8	10
291	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 264.	2.4	0
292	Educational Intervention to Improve Code Status Discussion Proficiency Among Obstetrics and Gynecology Residents. <i>American Journal of Hospice and Palliative Medicine</i> , 2018, 35, 724-730.	1.6	10
293	Failure to Rescue and Mortality Following Resection of Intracranial Neoplasms. <i>Neurosurgery</i> , 2018, 83, 263-269.	2.0	19
294	Effect of Minimum-Volume Standards on Patient Outcomes and Surgical Practice Patterns for Hysterectomy. <i>Obstetrics and Gynecology</i> , 2018, 132, 1229-1237.	1.9	13
295	Maternal age and risk for adverse outcomes. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 390.e1-390.e15.	2.4	174
296	Characteristics and outcomes of reproductive-aged women with early-stage cervical cancer: trachelectomy vs hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 461.e1-461.e18.	2.4	24
297	Use and outcomes of minimally invasive hysterectomy for women with nonendometrioid endometrial cancers. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 463.e1-463.e12.	2.4	22
298	Trends and Outcomes Associated With Using Long-Acting Opioids During Delivery Hospitalizations. <i>Obstetrics and Gynecology</i> , 2018, 132, 937-947.	1.9	18
299	Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 1905-1914.	34.6	631
300	Adherence to colonoscopy at 1 year following resection of localized colon cancer: a retrospective cohort study. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, .	3.2	10
301	Tumor-specific outcome of metachronous uterine malignancy after pelvic irradiation for cervical cancer. <i>Gynecologic Oncology</i> , 2018, 151, 250-256.	3.0	5
302	Assessment of Electronic Alert to Reduce Overuse of Granulocyte Colony-Stimulating Factor in Patients Hospitalized for Febrile Neutropenia. <i>JAMA Oncology</i> , 2018, 4, 996.	14.4	2
303	Postpartum hemorrhage outcomes and race. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 185.e1-185.e10.	2.4	123
304	Outcomes of Hysterectomy Performed by Very Low-Volume Surgeons. <i>Obstetrics and Gynecology</i> , 2018, 131, 981-990.	1.9	60
305	Characteristics associated with prolonged length of stay after hysterectomy for benign gynecologic conditions. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 89.e1-89.e15.	2.4	26
306	Postpartum venous thromboembolism readmissions in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 401.e1-401.e14.	2.4	36

#	ARTICLE	IF	CITATIONS
307	Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis. <i>Gynecologic Oncology</i> , 2018, 150, 501-508.	3.0	17
308	Patient reported outcomes in evaluation of chemotherapy toxicity in women with gynecologic malignancies: A pilot study. <i>Gynecologic Oncology</i> , 2018, 150, 487-493.	3.0	9
309	Trends in Use and Survival Associated With Fertility-Sparing Trachelectomy for Young Women With Early-Stage Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2018, 131, 1085-1094.	1.9	37
310	Association Between Temporal Changes in Neonatal Mortality and Spontaneous and Clinician-Initiated Deliveries in the United States, 2006-2013. <i>JAMA Pediatrics</i> , 2018, 172, 949.	8.6	28
311	Utilization of ovarian transposition for fertility preservation among young women with pelvic malignancies who undergo radiotherapy. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 415-417.	2.4	12
312	Changes in Surgical Volume and Outcomes Over Time for Women Undergoing Hysterectomy for Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2018, 132, 59-69.	1.9	28
313	Regional Market Competition and the Use of Immediate Breast Reconstruction After Mastectomy. <i>Annals of Surgical Oncology</i> , 2018, 26, 62-70.	2.3	11
314	Quality of Postoperative Venous Thromboembolism Prophylaxis in Neuro-oncologic Surgery. <i>Neurosurgery</i> , 2017, 80, 73-81.	2.0	14
315	Attitudes and Beliefs Regarding the Utility of Robotically Assisted Gynecologic Surgery Among Practicing Gynecologists. <i>Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality</i> , 2017, 39, 211-218.	0.9	7
316	Port Site Metastases: A Survey of the Society of Gynecologic Oncology and Commentary on the Clinical Workup and Management of Port Site Metastases. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 592-598.	0.8	6
317	Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1028-1037.	3.1	55
318	Physicians' Perspectives and Practice Patterns Toward Opportunistic Salpingectomy in High- and Low-Risk Women. <i>Cancer Investigation</i> , 2017, 35, 51-61.	1.6	26
319	Utilization of sentinel lymph node biopsy for uterine cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 594.e1-594.e13.	2.4	25
320	The role of maternal age in twin pregnancy outcomes. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 80.e1-80.e8.	2.4	62
321	Disparities in the management of ectopic pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 49.e1-49.e10.	2.4	50
322	Factors and Costs Associated With Delay in Treatment Initiation and Prolonged Length of Stay With Inpatient EPOCH Chemotherapy in Patients With Hematologic Malignancies. <i>Cancer Investigation</i> , 2017, 35, 202-214.	1.6	10
323	Trends in operative vaginal delivery, 2005–2013: a population-based study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1365-1372.	3.1	107
324	Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas. <i>International Journal of Cancer</i> , 2017, 140, 1396-1404.	4.3	59

#	ARTICLE	IF	CITATIONS
325	Case 16-2017 " A 69-Year-Old Woman with Urinary Incontinence. <i>New England Journal of Medicine</i> , 2017, 376, 2066-2073.	34.6	0
326	Sexual and Marital Dysfunction in Women With Gynecologic Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 603-607.	2.7	33
327	Patterns of Specialty-Based Referral and Perioperative Outcomes for Women With Endometrial Cancer Undergoing Hysterectomy. <i>Obstetrics and Gynecology</i> , 2017, 130, 81-90.	1.9	39
328	Utility of radiation therapy for early-stage uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , 2017, 145, 269-276.	3.0	32
329	Utilization of gynecologic services in women with breast cancer receiving hormonal therapy. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 59.e1-59.e12.	2.4	10
330	Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma. <i>Cancer</i> , 2017, 123, 1333-1344.	4.0	114
331	Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States. <i>JAMA Oncology</i> , 2017, 3, 705.	14.4	127
332	Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 558-564.	3.0	41
333	Surgical Antibiotic Prophylaxis and Risk for Postoperative Antibiotic-Resistant Infections. <i>Journal of the American College of Surgeons</i> , 2017, 225, 631-638.e3.	0.7	57
334	All-cause mortality in young women with endometrial cancer receiving progesterone therapy. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 669.e1-669.e13.	2.4	42
335	Trends in end-of-life care and health care spending in women with uterine cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 434.e1-434.e10.	2.4	22
336	Association between survival time with metastatic breast cancer and aggressive end-of-life care. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 549-558.	2.4	30
337	Association of Hospital Volume and Quality of Care With Survival for Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2017, 130, 545-553.	1.9	58
338	Venous Thromboembolism Prophylaxis During Antepartum Admissions and Postpartum Readmissions. <i>Obstetrics and Gynecology</i> , 2017, 130, 270-278.	1.9	13
339	Risk of Subsequent Ovarian Cancer After Ovarian Conservation in Young Women With Stage I Endometrioid Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2017, 130, 403-410.	1.9	35
340	Risk of metachronous ovarian cancer after ovarian conservation in young women with stage I cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 580.e1-580.e10.	2.4	20
341	Comparative Effectiveness of Cancer Control and Survival after Robot-Assisted versus Open Radical Prostatectomy. <i>Journal of Urology</i> , 2017, 197, 115-121.	4.2	62
342	Serious maternal complications in relation to severe pre-eclampsia: a retrospective cohort study of the impact of hospital volume. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1246-1253.	3.1	26

#	ARTICLE	IF	CITATIONS
343	Using publicly reported hospital data to predict obstetric quality. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017, 30, 1984-1991.	1.7	2
344	Severe maternal morbidity and comorbid risk in hospitals performing <1000 deliveries per year. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 179.e1-179.e12.	2.4	35
345	Gestational diabetes in the United States: temporal changes in prevalence rates between 1979 and 2010. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 804-813.	3.1	253
346	Laparoscopic staging for apparent stage I epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 50.e1-50.e12.	2.4	51
347	Inpatient Laparoscopic Hysterectomy in the United States: Trends and Factors Associated With Approach Selection. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 151-158.e1.	0.8	44
348	Cost of Care for the Initial Management of Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2017, 130, 1269-1275.	1.9	43
349	Practice Patterns, Attitudes, and Barriers to Palliative Care Consultation by Gynecologic Oncologists. <i>Journal of Oncology Practice</i> , 2017, 13, e703-e711.	2.9	45
350	The modified frailty index and 30-day adverse events in oncologic neurosurgery. <i>Journal of Neuro-Oncology</i> , 2017, 136, 197-206.	2.5	99
351	Surgical menopause and increased risk of nonalcoholic fatty liver disease in endometrial cancer. <i>Menopause</i> , 2016, 23, 189-196.	2.4	62
352	Axillary evaluation and lymphedema in women with ductal carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 373-384.	2.4	16
353	Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2016, 127, 109-118.	1.9	33
354	Trends in Periodic Surveillance Testing for Early-Stage Uterine Cancer Survivors. <i>Obstetrics and Gynecology</i> , 2016, 127, 449-458.	1.9	3
355	Utilization and Outcomes of Ovarian Conservation in Premenopausal Women With Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2016, 127, 101-108.	1.9	61
356	Utilization and Outcomes of Chemotherapy in Women With Intermediate-Risk, Early-Stage Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2016, 127, 992-1002.	1.9	13
357	Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2016, 127, 985-991.	1.9	23
358	Hospital variation in maternal complications following caesarean delivery in the United States: 2006-2012. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 1115-1120.	3.1	10
359	Measurement and validation of frailty as a predictor of outcomes in women undergoing major gynaecological surgery. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 455-461.	3.1	60
360	Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/Trail-Cisplatin combination therapy in cervical cancer. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 177-189.	3.0	20

#	ARTICLE	IF	CITATIONS
361	Nonadherence to Oral Medications for Chronic Conditions in Breast Cancer Survivors. <i>Journal of Oncology Practice</i> , 2016, 12, e800-e809.	2.9	38
362	Ovarian Conservation and Overall Survival in Young Women With Early-Stage Low-Grade Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2016, 128, 761-770.	1.9	68
363	Gastroschisis: epidemiology and mode of delivery, 2005–2013. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 348.e1-348.e9.	2.4	65
364	Perioperative Outcomes, Health Care Costs, and Survival After Robotic-assisted Versus Open Radical Cystectomy: A National Comparative Effectiveness Study. <i>European Urology</i> , 2016, 70, 195-202.	2.1	93
365	Safety, Utilization, and Cost of Image-Guided Percutaneous Liver Biopsy Among Cancer Patients. <i>Cancer Investigation</i> , 2016, 34, 189-196.	1.6	11
366	Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). <i>Breast Cancer Research and Treatment</i> , 2016, 157, 133-143.	2.4	55
367	Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery. <i>Gynecologic Oncology</i> , 2016, 141, 531-537.	3.0	23
368	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 134-135.	2.4	0
369	Use of Partial Nephrectomy after Acquisition of a Surgical Robot: A Population Based Study. <i>Urology Practice</i> , 2016, 3, 430-436.	1.3	9
370	Hospital delivery volume, severe obstetrical morbidity, and failure to rescue. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 795.e1-795.e14.	2.4	60
371	Population-based risk for peripartum hysterectomy during low- and moderate-risk delivery hospitalizations. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 640.e1-640.e8.	2.4	18
372	National trends in total pelvic exenteration for gynecologic malignancies. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 395-396.	2.4	8
373	Trends in Use and Outcomes of Women Undergoing Hysterectomy With Electric Power Morcellation. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 877.	16.6	42
374	Predictors of Interventional Treatment Use for Venous Thromboembolism in Cancer Patients. <i>Cancer Investigation</i> , 2016, 34, 408-414.	1.6	1
375	Utilization and Outcomes of Sentinel Lymph Node Biopsy for Vulvar Cancer. <i>Obstetrics and Gynecology</i> , 2016, 128, 754-760.	1.9	21
376	Characteristics, treatment and outcomes of women with immature ovarian teratoma, 1998–2012. <i>Gynecologic Oncology</i> , 2016, 142, 261-266.	3.0	43
377	Impact of the 2014 Food and Drug Administration Warnings Against Power Morcellation. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 548-556.	0.8	48
378	Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1326.	14.4	70

#	ARTICLE	IF	CITATIONS
379	Magnitude of risk for nodal metastasis associated with lymphovascular space invasion for endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 140, 387-393.	3.0	64
380	Radiation Duration in Women with Cervical Cancer Treated with Primary Chemoradiation: A Population-Based Analysis. <i>Cancer Investigation</i> , 2016, 34, 137-147.	1.6	22
381	Natural history and outcome of neuroendocrine carcinoma of the cervix. <i>Gynecologic Oncology</i> , 2016, 141, 247-254.	3.0	89
382	Effect of Regional Hospital Competition and Hospital Financial Status on the Use of Robotic-Assisted Surgery. <i>JAMA Surgery</i> , 2016, 151, 612.	8.8	109
383	Applying to subspecialty fellowship: clarifying the confusion and conflicts!. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 243-246.	2.4	15
384	Comparative outcomes in older and younger women undergoing laparotomy or robotic surgical staging for endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 350.e1-350.e10.	2.4	42
385	Underuse of BRCA testing in patients with breast and ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 761-763.	2.4	32
386	Overuse of external beam radiotherapy for stage I endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 75.e1-75.e7.	2.4	8
387	Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 453.	14.4	93
388	Severe placental abruption: clinical definition and associations with maternal complications. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 272.e1-272.e9.	2.4	115
389	An economic analysis of trial of labor after cesarean delivery. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2016, 29, 1030-1035.	1.7	3
390	Population-based assessment of determining predictors for quality of prostate cancer surveillance. <i>Cancer</i> , 2015, 121, 4150-4157.	4.0	24
391	Trends in Relative Survival for Ovarian Cancer From 1975 to 2011. <i>Obstetrics and Gynecology</i> , 2015, 125, 1345-1352.	1.9	111
392	Factors Associated With 30-Day Hospital Readmission After Hysterectomy. <i>Obstetrics and Gynecology</i> , 2015, 125, 461-470.	1.9	33
393	Complications Following Stereotactic Needle Biopsy of Intracranial Tumors. <i>World Neurosurgery</i> , 2015, 84, 1084-1089.	1.5	152
394	Risk stratification and outcomes of women undergoing surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 62-69.	3.0	46
395	Use of Electric Power Morcellation and Prevalence of Underlying Cancer in Women Who Undergo Myomectomy. <i>JAMA Oncology</i> , 2015, 1, 69.	14.4	65
396	Influence of treatment center and hospital volume on survival for locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2015, 139, 506-512.	3.0	58

#	ARTICLE	IF	CITATIONS
397	High versus low-dose rate brachytherapy for cervical cancer. <i>Gynecologic Oncology</i> , 2015, 136, 534-541.	3.0	25
398	Reply to A. Kolacevski et al. <i>Journal of Oncology Practice</i> , 2015, 11, 71-71.	2.9	0
399	Trends in Use and Safety of Image-Guided Transthoracic Needle Biopsies in Patients With Cancer. <i>Journal of Oncology Practice</i> , 2015, 11, e351-e359.	2.9	26
400	The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ. <i>JAMA Oncology</i> , 2015, 1, 323.	14.4	29
401	Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2015, 138, 620-626.	3.0	35
402	Relationship Between Surgical Oncologic Outcomes and Publically Reported Hospital Quality and Satisfaction Measures. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	4.6	15
403	Long-term mortality among women with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 421-428.	3.0	63
404	Quality and Outcomes of Treatment of Hypercalcemia of Malignancy. <i>Cancer Investigation</i> , 2015, 33, 331-339.	1.6	42
405	Variation in and Factors Associated With Use of Episiotomy. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 197.	16.6	74
406	Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 137, 203-209.	3.0	18
407	Conservative management of morbidly adherent placenta: expert review. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 755-760.	2.4	186
408	Evaluation of Third-Degree and Fourth-Degree Laceration Rates as Quality Indicators. <i>Obstetrics and Gynecology</i> , 2015, 125, 927-937.	1.9	120
409	Center of excellence for placenta accreta. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 561-568.	2.4	466
410	Population-level trends in relative survival for cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 670.e1-670.e7.	2.4	45
411	Thromboembolism incidence and prophylaxis during vaginal delivery hospitalizations. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 221.e1-221.e12.	2.4	38
412	Erythropoiesis-Stimulating Agent Use After Changes in Medicare Reimbursement Policies. <i>Journal of Oncology Practice</i> , 2014, 10, 264-269.	2.9	11
413	The Change From Brand-Name to Generic Aromatase Inhibitors and Hormone Therapy Adherence for Early-Stage Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	4.6	93
414	Comparative Effectiveness of Robotically Assisted Compared With Laparoscopic Adnexal Surgery for Benign Gynecologic Disease. <i>Obstetrics and Gynecology</i> , 2014, 124, 886-896.	1.9	20

#	ARTICLE	IF	CITATIONS
415	Patterns of Use and Predictors of Receipt of Antibiotics in Women Undergoing Cesarean Delivery. <i>Obstetrics and Gynecology</i> , 2014, 124, 338-344.	1.9	15
416	Uterine Pathology in Women Undergoing Minimally Invasive Hysterectomy Using Morcellation. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1253.	16.6	134
417	Measure for Measure: The Cost of Improving Quality. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	4.6	2
418	An Economic Analysis of Robotically Assisted Hysterectomy. <i>Obstetrics and Gynecology</i> , 2014, 123, 1038-1048.	1.9	91
419	Utility of cell salvage in women undergoing abdominal myomectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 28.e1-28.e8.	2.4	8
420	Safety and Tolerance of Radical Hysterectomy for Cervical Cancer in the Elderly. <i>Gynecologic Oncology</i> , 2014, 134, 36-41.	3.0	26
421	Surgical management of placenta accreta: to leave or remove the placenta?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 163-170.	3.1	59
422	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 441.	2.4	0
423	Patterns of use of hemostatic agents in patients undergoing major surgery. <i>Journal of Surgical Research</i> , 2014, 186, 458-466.	1.6	64
424	Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer. <i>Cancer</i> , 2014, 120, 1246-1254.	4.0	81
425	Fraction of cell-free fetal DNA in the maternal serum as a predictor of abnormal placental invasion—a pilot study. <i>Prenatal Diagnosis</i> , 2013, 33, 1050-1053.	2.3	32
426	Failure to rescue after major gynecologic surgery. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 420.e1-420.e8.	2.4	31
427	Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. <i>Gynecologic Oncology</i> , 2013, 130, 64-68.	3.0	81
428	Carcinosarcoma of the ovary: Natural history, patterns of treatment, and outcome. <i>Gynecologic Oncology</i> , 2013, 131, 42-45.	3.0	62
429	Patterns of care for locally advanced vulvar cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 60.e1-60.e5.	2.4	12
430	Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2013, 131, 535-540.	3.0	25
431	Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. <i>Gynecologic Oncology</i> , 2013, 128, 77-82.	3.0	126
432	Bowel obstruction in elderly ovarian cancer patients: A population-based study. <i>Gynecologic Oncology</i> , 2013, 129, 107-112.	3.0	46

#	ARTICLE	IF	CITATIONS
433	Uptake and outcomes of intensity-modulated radiation therapy for uterine cancer. <i>Gynecologic Oncology</i> , 2013, 130, 43-48.	3.0	23
434	Take 'em or leave 'em: Management of the ovaries in young women with endometrial cancer. <i>Gynecologic Oncology</i> , 2013, 131, 287-288.	3.0	17
435	Practice patterns and knowledge of obstetricians and gynecologists regarding placenta accreta. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2013, 26, 1602-1609.	1.7	56
436	Variation in Ovarian Conservation in Women Undergoing Hysterectomy for Benign Indications. <i>Obstetrics and Gynecology</i> , 2013, 121, 717-726.	1.9	40
437	Robotically Assisted vs Laparoscopic Hysterectomy Among Women With Benign Gynecologic Disease. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 689.	16.6	504
438	Contemporary Clinical Management of Endometrial Cancer. <i>Obstetrics and Gynecology International</i> , 2013, 2013, 1-11.	1.0	41
439	Prognostic Significance of Mucinous Differentiation of Endometrioid Adenocarcinoma of the Endometrium. <i>Cancer Investigation</i> , 2013, 31, 500-504.	1.6	13
440	Comparison between emergent and elective delivery in women with placenta accreta. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2013, 26, 1007-1011.	1.7	28
441	Underuse of Postcesarean Thromboembolism Prophylaxis. <i>Obstetrics and Gynecology</i> , 2013, 122, 1197-1204.	1.9	40
442	Incidence and Predictors of Bowel Obstruction in Elderly Patients With Stage IV Colon Cancer. <i>JAMA Surgery</i> , 2013, 148, 715.	8.8	121
443	Deviations From Guideline-Based Therapy for Febrile Neutropenia in Cancer Patients and Their Effect on Outcomes. <i>JAMA Internal Medicine</i> , 2013, 173, 559.	10.5	104
444	Use of Guideline-Based Antibiotic Prophylaxis in Women Undergoing Gynecologic Surgery. <i>Obstetrics and Gynecology</i> , 2013, 122, 1145-1153.	1.9	37
445	Nationwide Trends in the Performance of Inpatient Hysterectomy in the United States. <i>Obstetrics and Gynecology</i> , 2013, 122, 233-241.	1.9	644
446	Trends in Hospital Volume and Patterns of Referral for Women With Gynecologic Cancers. <i>Obstetrics and Gynecology</i> , 2013, 121, 1217-1225.	1.9	18
447	The Risk of Lymph Node Metastasis With Positive Peritoneal Cytology in Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 90-97.	2.7	15
448	Nationwide practice patterns for the use of venous thromboembolism prophylaxis among men undergoing radical prostatectomy. <i>World Journal of Urology</i> , 2013, 32, 1313-1321.	2.3	27
449	NOTCH2 expression is decreased in epithelial ovarian cancer and is related to the tumor histological subtype. <i>Pathology Discovery</i> , 2013, 1, 4.	0.0	13
450	Reply to C.A. Hudis et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 3150-3150.	16.9	0

#	ARTICLE	IF	CITATIONS
451	Uptake and Economic Impact of First-Cycle Colony-Stimulating Factor Use During Adjuvant Treatment of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 806-812.	16.9	27
452	Comparative effectiveness of robotic gynecologic surgery. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 377-379.	2.2	1
453	Comparative Effectiveness Research in Oncology Methodology: Observational Data. <i>Journal of Clinical Oncology</i> , 2012, 30, 4215-4222.	16.9	132
454	Use and Benefits of Laparoscopic Hysterectomy for Stage I Endometrial Cancer Among Medicare Beneficiaries. <i>Journal of Oncology Practice</i> , 2012, 8, e89-e99.	2.9	24
455	Acceptance and Compliance With Postpartum Human Papillomavirus Vaccination. <i>Obstetrics and Gynecology</i> , 2012, 120, 771-782.	1.9	29
456	Effect of Radical Cytoreductive Surgery on Omission and Delay of Chemotherapy for Advanced-Stage Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2012, 120, 871-881.	1.9	96
457	Effect of Surgical Volume on Outcomes for Laparoscopic Hysterectomy for Benign Indications. <i>Obstetrics and Gynecology</i> , 2012, 119, 709-716.	1.9	127
458	Contemporary management of endometrial cancer. <i>Lancet, The</i> , 2012, 379, 1352-1360.	62.3	255
459	Influence of health insurance, hospital factors and physician volume on receipt of immediate post-mastectomy reconstruction in women with invasive and non-invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 535-545.	2.4	74
460	Comparative effectiveness of minimally invasive and abdominal radical hysterectomy for cervical cancer. <i>Gynecologic Oncology</i> , 2012, 127, 11-17.	3.0	133
461	Re: Prognostic significance of adenocarcinoma histology in women with cervical cancer. <i>Gynecologic Oncology</i> , 2012, 127, 260.	3.0	2
462	The commercialization of robotic surgery: unsubstantiated marketing of gynecologic surgery by hospitals. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 207, 174.e1-174.e7.	2.4	57
463	Feasibility and economic impact of same-day discharge for women who undergo laparoscopic hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 207, 382.e1-382.e9.	2.4	100
464	Patterns of care and treatment outcomes for elderly women with cervical cancer. <i>Cancer</i> , 2012, 118, 3618-3626.	4.0	109
465	Completion of and early response to chemoradiation among human immunodeficiency virus (HIV)-positive and HIV-negative patients with locally advanced cervical carcinoma in South Africa. <i>Cancer</i> , 2012, 118, 2971-2979.	4.0	50
466	Microinvasive adenocarcinoma of the cervix. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, 80.e1-80.e6.	2.4	34
467	Prognostic significance of adenocarcinoma histology in women with cervical cancer. <i>Gynecologic Oncology</i> , 2012, 125, 287-291.	3.0	238
468	Defining the limits of radical cytoreductive surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2012, 125, 508-509.	3.0	0

#	ARTICLE	IF	CITATIONS
469	Trends in Surgical Mesh Use for Pelvic Organ Prolapse From 2000 to 2010. <i>Obstetrics and Gynecology</i> , 2012, 120, 1105-1115.	1.9	61
470	Risk and Predictors of Malignancy in Women with Endometrial Polyps. <i>Annals of Surgical Oncology</i> , 2011, 18, 3819-3823.	2.3	54
471	Quality of Venous Thromboembolism Prophylaxis in Patients Undergoing Oncologic Surgery. <i>Annals of Surgery</i> , 2011, 253, 1140-1146.	4.6	31
472	Quality of Perioperative Venous Thromboembolism Prophylaxis in Gynecologic Surgery. <i>Obstetrics and Gynecology</i> , 2011, 118, 978-986.	1.9	17
473	Effect of Surgical Volume on Morbidity and Mortality of Abdominal Hysterectomy for Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2011, 117, 1051-1059.	1.9	50
474	Transfusion requirements in obstetric patients with placenta accreta. <i>Transfusion</i> , 2011, 51, 2627-2633.	0.8	79
475	Endometrial cancer in the oldest old: Tumor characteristics, patterns of care, and outcome. <i>Gynecologic Oncology</i> , 2011, 122, 69-74.	3.0	68
476	High-grade uterine sarcoma during pregnancy. <i>Gynecologic Oncology</i> , 2011, 123, 424-425.	3.0	4
477	Evaluating the significance of location of lymph node metastasis and extranodal disease in women with stage IIIC endometrial cancer. <i>Gynecologic Oncology</i> , 2011, 123, 208-213.	3.0	28
478	Defining the limits of radical cytoreductive surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 123, 467-473.	3.0	86
479	Comparison of the prognostic significance of uterine factors and nodal status for endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, 248.e1-248.e7.	2.4	20
480	Predictors of massive blood loss in women with placenta accreta. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 38.e1-38.e6.	2.4	118
481	Morbidity and mortality of surgery for endometrial cancer in the oldest old. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 66.e1-66.e8.	2.4	31
482	The influence of surgical volume on morbidity and mortality of radical hysterectomy for cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 225.e1-225.e7.	2.4	45
483	Natural history and outcome of mucinous carcinoma of the ovary. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 480.e1-480.e8.	2.4	98
484	Lymphadenectomy influences the utilization of adjuvant radiation treatment for endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 205, 562.e1-562.e9.	2.4	63
485	Therapeutic role of lymphadenectomy for cervical cancer. <i>Cancer</i> , 2011, 117, 310-317.	4.0	56
486	Management of Endometrial Cancer in Young Women. <i>Clinical Obstetrics and Gynecology</i> , 2011, 54, 219-225.	1.2	21

#	ARTICLE	IF	CITATIONS
487	Scientific Evidence Underlying the American College of Obstetricians and Gynecologists' Practice Bulletins. <i>Obstetrics and Gynecology</i> , 2011, 118, 505-512.	1.9	69
488	Venous Thromboembolism and Use of Prophylaxis Among Women Undergoing Laparoscopic Hysterectomy. <i>Obstetrics and Gynecology</i> , 2011, 117, 1367-1374.	1.9	53
489	Paclitaxel poliglumex for ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 813-821.	3.9	58
490	Influence of Surgical Volume on Outcome for Laparoscopic Hysterectomy for Endometrial Cancer. <i>Annals of Surgical Oncology</i> , 2011, 19, 948-958.	2.3	51
491	Uterine carcinosarcoma. <i>Current Opinion in Oncology</i> , 2011, 23, 531-536.	2.1	70
492	Fertility-Conserving Surgery for Young Women With Stage IA1 Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2010, 115, 585-590.	1.9	69
493	Peripartum Hysterectomy. <i>Obstetrics and Gynecology</i> , 2010, 116, 429-434.	1.9	32
494	Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics's Staging System for Uterine Corpus Cancer. <i>Obstetrics and Gynecology</i> , 2010, 116, 1141-1149.	1.9	302
495	The Effect of Surgeon Volume on Outcomes and Resource Use for Vaginal Hysterectomy. <i>Obstetrics and Gynecology</i> , 2010, 116, 1341-1347.	1.9	89
496	Long-term outcome and natural history of uterine adenosarcomas. <i>Gynecologic Oncology</i> , 2010, 119, 305-308.	3.0	106
497	Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. <i>Cancer</i> , 2010, 116, 2486-2492.	4.0	50
498	Targeted Therapies in Epithelial Ovarian Cancer. <i>Journal of Oncology</i> , 2010, 2010, 1-9.	3.9	18
499	Regionalization of Care for Obstetric Hemorrhage and Its Effect on Maternal Mortality. <i>Obstetrics and Gynecology</i> , 2010, 115, 1194-1200.	1.9	108
500	Morbidity and Mortality of Peripartum Hysterectomy. <i>Obstetrics and Gynecology</i> , 2010, 115, 1187-1193.	1.9	129
501	Stage IIIA Endometrial Carcinoma. <i>Obstetrics and Gynecology</i> , 2009, 114, 100-105.	1.9	19
502	Long-term assessment of bladder and bowel dysfunction after radical hysterectomy. <i>Gynecologic Oncology</i> , 2009, 114, 75-79.	3.0	49
503	Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery. <i>Gynecologic Oncology</i> , 2009, 115, 18-25.	3.0	64
504	Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, 419.e1-419.e7.	2.4	49

#	ARTICLE	IF	CITATIONS
505	Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 201, 485.e1-485.e9.	2.4	107
506	Surgical Intervention in the Management of Postpartum Hemorrhage. <i>Seminars in Perinatology</i> , 2009, 33, 109-115.	2.3	32
507	Racial disparities for uterine corpus tumors. <i>Cancer</i> , 2009, 115, 1276-1285.	4.0	136
508	Fertility preservation in young women with epithelial ovarian cancer. <i>Cancer</i> , 2009, 115, 4118-4126.	4.0	135
509	Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 983-992.	3.0	63
510	Peritoneal Inclusion Cysts. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 321-334.	0.5	90
511	Improved survival for fallopian tube cancer. <i>Cancer</i> , 2008, 113, 3298-3306.	4.0	66
512	Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: Potential role in progression. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 755-765.	3.0	304
513	The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, 536.e1-536.e8.	2.4	81
514	Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. <i>British Journal of Cancer</i> , 2008, 98, 1197-1203.	5.5	88
515	A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 400-406.	2.7	39
516	Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 1194-1199.	2.7	12
517	Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: A multi-institutional review. <i>Gynecologic Oncology</i> , 2008, 108, 293-297.	3.0	99
518	The current and future role of screening in the era of HPV vaccination. <i>Gynecologic Oncology</i> , 2008, 109, S31-S39.	3.0	28
519	Clear cell carcinoma of the cervix: A multi-institutional review in the post-DES era. <i>Gynecologic Oncology</i> , 2008, 109, 335-339.	3.0	90
520	Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2008, 109, 353-358.	3.0	58
521	The utility of preoperative endometrial sampling for the detection of uterine sarcomas. <i>Gynecologic Oncology</i> , 2008, 110, 43-48.	3.0	138
522	The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies. <i>Gynecologic Oncology</i> , 2008, 111, 208-212.	3.0	34

#	ARTICLE	IF	CITATIONS
523	Clinical Indications for Human Papillomavirus Vaccination. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2008, 1, 36-39.	0.5	0
524	Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. <i>Molecular Cancer</i> , 2008, 7, .	29.2	107
525	Uterine Carcinosarcomas and Grade 3 Endometrioid Cancers. <i>Obstetrics and Gynecology</i> , 2008, 112, 64-70.	1.9	115
526	Current treatment strategies for endometrial cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1149-1157.	2.5	12
527	Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy. <i>Cancer</i> , 2007, 110, 1281-1286.	4.0	196
528	A vascular graft for endometrial cancer groin recurrence. <i>Gynecologic Oncology</i> , 2007, 104, 753-756.	3.0	0
529	Effect of a T0 radical hysterectomy specimen on survival for early stage cervical cancer. <i>Gynecologic Oncology</i> , 2007, 107, 280-284.	3.0	1
530	The impact of cervical cancer on quality of life. The components and means for management. <i>Gynecologic Oncology</i> , 2007, 107, 572-577.	3.0	92
531	Uterine leiomyosarcomas. <i>Women's Oncology Review</i> , 2006, 6, 121-126.	0.0	0
532	Human Papillomavirus Triage for Young Women With Atypical Squamous Cells of Undetermined Significance. <i>Obstetrics and Gynecology</i> , 2006, 107, 822-829.	1.9	18
533	Long-term outcome of women who undergo panniculectomy at the time of gynecologic surgery. <i>Gynecologic Oncology</i> , 2006, 102, 86-91.	3.0	18
534	Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2006, 103, 489-493.	3.0	87
535	Colposcopic accuracy of obstetrics and gynecology residents. <i>Gynecologic Oncology</i> , 2006, 103, 966-970.	3.0	43
536	Cervical cancer prevention in the era of prophylactic vaccines: A preview for gynecologic oncologists. <i>Gynecologic Oncology</i> , 2006, 102, 552-562.	3.0	42
537	Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma. <i>Cancer</i> , 2006, 107, 83-89.	4.0	131
538	Cervical Dysplasia in Adolescents. <i>Obstetrics and Gynecology</i> , 2005, 106, 115-120.	1.9	53
539	Persistent and recurrent cervical dysplasia after loop electrosurgical excision procedure. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 192, 1379-1381.	2.4	38
540	Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. <i>Gynecologic Oncology</i> , 2005, 98, 84-91.	3.0	23

#	ARTICLE	IF	CITATIONS
541	Cervical sarcomas: An analysis of incidence and outcome. <i>Gynecologic Oncology</i> , 2005, 99, 348-351.	3.0	67
542	Cervical carcinoma in the elderly. <i>Cancer</i> , 2005, 103, 85-91.	4.0	84
543	Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. <i>Cancer</i> , 2005, 104, 2484-2491.	4.0	170
544	Synchronous ovarian metastases at the time of laparotomy for colon cancer. <i>Gynecologic Oncology</i> , 2004, 92, 851-855.	3.0	48
545	Panniculectomy: improving lymph node yield in morbidly obese patients with endometrial neoplasms. <i>Gynecologic Oncology</i> , 2004, 94, 436-441.	3.0	27
546	A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?. <i>Gynecologic Oncology</i> , 2004, 95, 70-76.	3.0	46
547	Morbidity of cytoreductive surgery in the elderly. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 1398-1400.	2.4	68
548	Is hypotonic dysfunctional labor associated with hypophosphatemia?. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 1447-1449.	2.4	0
549	Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies. <i>Gynecologic Oncology</i> , 2003, 91, 134-138.	3.0	16
550	Acute abdominal pain with a calcified pelvic mass. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2003, 16, 237-241.	0.7	3
551	Treatment of High-Risk Gestational Trophoblastic Tumors. <i>Clinical Obstetrics and Gynecology</i> , 2003, 46, 593-606.	1.2	19
552	Placental site trophoblastic tumor presenting with a pneumothorax during pregnancy. <i>Obstetrics and Gynecology</i> , 2002, 100, 1141-1144.	1.9	11
553	Coordinate Regulation of Prostaglandin Metabolism for Induction of Parturition in Mice. <i>Endocrinology</i> , 2002, 143, 2593-2598.	2.5	13
554	Diabetes Technology Use in Pregnancies with Type 1 Diabetes in the United States from 2009 to 2020. <i>American Journal of Perinatology</i> , 0, 43, 453-460.	1.7	0
555	Emergency cesarean hysterectomy for placenta accreta spectrum: Estimation of maternal morbidity and mortality. <i>International Journal of Gynecology and Obstetrics</i> , 0, 171, 1414-1417.	1.8	0
556	Survival After Fertility-Preserving Hormonal Therapy vs Hysterectomy for Early-Stage Endometrial Cancer. <i>JAMA Oncology</i> , 0, 11, 1212.	14.4	6
557	Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol. <i>Gynecologic Oncology</i> , 0, 201, 184-194.	3.0	0
558	Physician variation in adopting opportunistic salpingectomy at the time of postpartum and interval sterilization for ovarian cancer risk reduction. <i>Gynecologic Oncology</i> , 0, 202, 1-13.	3.0	0

#	ARTICLE	IF	CITATIONS
559	Physician Peer Influence on Salpingectomy Uptake for Tubal Sterilization and Ovarian Cancer Prevention. <i>JAMA Network Open</i> , 0, 8, e2532998.	6.6	1
560	Performance of ultrasound and rates of guideline-concordant care in a diverse postmenopausal bleeding cohort. <i>American Journal of Obstetrics and Gynecology</i> , 0, 234, 400-416.	2.4	1
561	Population-Level Reduction in Ovarian Cancer Through Performance of Opportunistic Salpingectomy at the Time of Cholecystectomy. <i>Annals of Surgery</i> , 0, , .	4.6	0
562	Postmenopausal bleeding: Association of initial place of care with stage at diagnosis for uterine cancer. <i>Gynecologic Oncology</i> , 0, 203, 75-83.	3.0	0
563	Physician-level variability in adopting opportunistic salpingectomy for ovarian cancer prevention at the time of hysterectomy. <i>International Journal of Gynecological Cancer</i> , 0, 36, 102769.	2.7	0
564	Disparities in delays and outcomes in patients with HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 0, 215, .	2.4	0
565	Concerns in the Propensity Score“Matched Analysis”Reply. <i>JAMA Oncology</i> , 0, , .	14.4	0
566	Neoadjuvant Chemotherapy Versus Primary Cytoreductive Surgery for Metastatic Endometrial Cancer. <i>Cancer Medicine</i> , 0, 15, .	2.6	0